IDH mutations are present in 20% of acute myeloid leukemia (AML) patients and the use of IDH-targeting agents has shown favorable clinical responses in AML, with ivosidenib and enasidenib (IDH1 and IDH2 inhibitors) being approved by the US F.D.A for relapsed/refractory AML patients.
In this podcast, Amir Fathi of Massachusetts General Hospital, Boston, MA, chairs a panel discussion evaluating the use of IDH inhibitors in AML and myelodysplastic syndromes, the potential of combination therapies using these agents, and the development of differentiation syndrome in AML. Dr Fathi is joined by Stephane De Botton of Gustave Roussy Institute, Villejuif, France, and Daniel Pollyea of the University of Colorado, Denver, CO.
The post The AML Sessions: IDH inhibitors appeared first on VJHemOnc.
